We have previously shown that immunodeficient mice exhibit significant facial motoneuron (FMN) loss compared to wild-type (WT) mice after a facial nerve axotomy. Interleukin-10 (IL-10) is known as a regulatory cytokine that plays an important role in maintaining the anti-inflammatory environment within the central nervous system (CNS). IL-10 is produced by a number of different cells, including Th2 cells, and may exert an anti-apoptotic action on neurons directly. In the present study, the role of IL-10 in mediating neuroprotection following facial nerve axotomy in Rag-2-and IL-10-deficient mice was investigated. Results indicate that IL-10 is neuroprotective, but CD4 + T cells are not the requisite source of IL-10. In addition, using real-time PCR analysis of laser microdissected brainstem sections, results show that IL-10 mRNA is constitutively expressed in the facial nucleus and that a transient, significant reduction of IL-10 mRNA occurs following axotomy under immunodeficient conditions. Dual labeling immunofluorescence data show, unexpectedly, that the IL-10 receptor (IL-10R) is constitutively expressed by facial motoneurons, but is selectively induced in astrocytes within the facial nucleus after axotomy. Thus, a non-CD4 + T cell source of IL-10 is necessary for modulating both glial and neuronal events that mediate neuroprotection of injured motoneurons, but only with the cooperation of CD4 + T cells, providing an avenue of novel investigation into therapeutic approaches to prevent or reverse motoneuron diseases, such as amyotrophic lateral sclerosis (ALS).
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Introduction
Neurons are differentiated cells that lack the capacity to divide. Therefore, the loss of a neuron due to nerve injury prevents nerve regeneration and functional recovery from taking place, primarily because essential proteins needed for nerve repair are no longer produced in the absence of the cell body. Therefore, supporting neuronal survival during a neuroinflammatory disease process or after a nerve injury is vitally important to prevent loss of nerve function. One mechanism that appears to determine if neurodestruction or neuroprotection occurs within the CNS involves the nature and extent of the immune response that develops. It is generally thought that pro-inflammatory responses are detrimental, while anti-inflammatory responses are beneficial (Steinman, 2004; Griffiths et al., 2007; Stoll et al., 2002) . Several immunotherapies have been investigated and proven to be effective for the treatment of neurological disorders, e.g., glatiramer acetate (GA) for multiple sclerosis (MS) and beta-amyloid vaccine for Alzheimer's disease (Ruggieri et al., 2007; Hawkes and McLaurin, 2007) . As a result, preventing or ameliorating neurological disease through immunotherapy has become an important research topic for drug discovery and clinical treatment of neurological disorders (Hawkes and McLaurin, 2007; De Jager and Hafler, 2007) , although the mechanisms by which current immunotherapies exert their effects are not well understood.
Previous studies utilizing the facial nerve axotomy model have revealed that a competent immune system, particularly with respect to the CD4 + T cell, is necessary for promoting facial motoneuron (FMN) survival after facial nerve injury (Serpe et al., 1999 (Serpe et al., , 2000 (Serpe et al., , 2003 . Recently, we reported that multiple subsets of CD4 + cells, 
